Abstract

BACKGROUND: Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibitors (ICI) may be considered for treatment as illustrated in the present case report.

CASE: We report a patient with ACTH-secreting pituitary carcinoma, progressive after multiple lines of therapy including chemotherapy with TMZ, who demonstrated disease stabilization by a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) ICI therapy.

DISCUSSION: Management of pituitary carcinoma beyond TMZ remains ill-defined and relies on case reports. TMZ creates, due to hypermutation, more immunogenic tumors and subsequently potential candidates for ICI therapy. This case report adds support to the possible role of ICI in the treatment of pituitary carcinoma.

CONCLUSION: ICI therapy could be a promising treatment option for pituitary carcinoma, considering the mechanisms of TMZ-induced hypermutation with increased immunogenicity, pituitary expression of CTLA-4 and PD-L1, and the frequent occurrence of hypophysitis as a side effect of ICI therapy.

Original languageEnglish
Pages (from-to)K1-K5
Number of pages5
JournalEuropean Journal of Endocrinology
Volume184
Issue number1
Early online date2020
DOIs
Publication statusPublished - Jan 2021

Keywords

  • ACTH-Secreting Pituitary Carcinoma:
  • Immune Checkpoint Inhibitor Therapy
  • treatment

Fingerprint

Dive into the research topics of 'Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma: a new emerging treatment?'. Together they form a unique fingerprint.

Cite this